文献速递糖尿病

接受达格列净治疗的糖尿病患者全因死亡率:基于健康改善网络数据库的人群队列研究

All-Cause Mortality in Patients With Diabetes Under Treatment With Dapagliflozin: A Population-Based, Open-Cohort Study in The Health Improvement Network Database.
PubMed 文献 · J Clin Endocrinol Metab · 2017-01-01

基于健康改善网络数据库的回顾性开放队列研究,纳入22124例2型糖尿病患者(达格列净暴露4444例,非暴露17680例),按年龄、性别、体质指数、糖尿病病程和吸烟匹配。达格列净暴露者全因死亡风险显著降低(aIRR 0.50,95%CI 0.33-0.75,P=0.001),低心血管风险亚组同样显著降低(aIRR 0.44,95%CI 0.25-0.78,P=0.002),但新发心血管疾病风险组间无显著差异(aIRR 0.89,95%CI 0.61-1.31,P=0.546)。

要点

  • 达格列净暴露的2型糖尿病患者全因死亡风险显著降低(aIRR 0.50,95%CI 0.33-0.75)。
  • 低心血管风险患者中达格列净暴露者全因死亡风险亦显著降低(aIRR 0.44,95%CI 0.25-0.78)。
  • 低心血管风险患者中新发心血管疾病风险组间无显著差异(aIRR 0.89,95%CI 0.61-1.31)。

核心结论

  • 暴露于达格列净的2型糖尿病患者全因死亡风险较低,且不受基线心血管疾病状态影响。

研究设计与样本

  • 一般实践、基于人群的回顾性队列研究,时间范围为2013年1月至2015年9月。
  • 数据来源为健康改善网络(The Health Improvement Network)数据库。
  • 共纳入22124例2型糖尿病患者,其中达格列净暴露4444例,非暴露17680例,按年龄、性别、体质指数、糖尿病病程和吸烟进行匹配。

主要发现

  • 达格列净暴露的2型糖尿病患者全因死亡风险显著低于非暴露组(aIRR 0.50,95%CI 0.33-0.75,P=0.001)。
  • 低心血管风险患者中,达格列净暴露组全因死亡风险显著低于非暴露组(aIRR 0.44,95%CI 0.25-0.78,P=0.002)。
  • 低心血管风险患者中新发心血管疾病风险组间无显著差异(aIRR 0.89,95%CI 0.61-1.31,P=0.546)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Empagliflozin was found to decrease mortality in patients with type 2 diabetes mellitus (T2DM) and a prior cardiovascular disease (CVD) event. OBJECTIVES: To establish whether these benefits can be replicated in a real-world setting, should be expected with the use of dapagliflozin, and apply to T2DM patients at low risk of CVD. DESIGN: General practice, population-based, retrospective cohort study (January 2013 to September 2015). SETTING: The Health Improvement Network database. PARTICIPANTS: A total of 22,124 T2DM patients (4444 exposed to dapagliflozin; 17,680 unexposed T2DM patients) matched for age, sex, body mass index, T2DM duration, and smoking. MAIN OUTCOME MEASURES: The primary outcome was all-cause mortality (high and low risk for CVD) in the total study population, expressed as the adjusted incidence rate ratio (aIRR) with 95% confidence intervals (CIs). As a secondary analysis in the low-risk population, all-cause mortality and incident CVD were considered. RESULTS: Patients with T2DM exposed to dapagliflozin were significantly less likely to die of any cause (aIRR: 0.50; 95% CI: 0.33 to 0.75; P = 0.001). Similarly, in low-risk patients, death from any cause was significantly lower in the cohort exposed to dapagliflozin (aIRR: 0.44; 95% CI: 0.25 to 0.78; P = 0.002). The difference in the risk of incident CVD did not reach statistical significance between groups in low-risk patients (aIRR: 0.89; 95% CI: 0.61 to 1.31; P = 0.546). CONCLUSIONS: Patients with T2DM who were exposed to dapagliflozin had a lower risk of death from any cause irrespective of baseline CVD status.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Toulis KA, Willis BH, Marshall T, et al. All-Cause Mortality in Patients With Diabetes Under Treatment With Dapagliflozin: A Population-Based, Open-Cohort Study in The Health Improvement Network Database. J Clin Endocrinol Metab. 2017. PMID: 28323967. doi:10.1210/jc.2016-3446

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。